Direct Rx recalls 0.5% moxifloxacin eye drops due to stability concerns. Affected lots expire 4/30/23. Contact for return instructions.
cGMP deviation: discontinue of stability support for product.
Direct Rx is recalling certain moxifloxacin eye drops because they may not stay stable after production. This could affect the medicine's effectiveness if used.
The eye drops were produced without proper stability testing, which means they might not work correctly over time. This could lead to ineffective treatment for eye infections.
Prescription eye drop users who purchased the specific lot (07MA2232) from Direct Rx. People with eye conditions requiring this medication are most at risk.
Check for the lot number 07MA2232 on the packaging. The product expires April 30, 2023. Only the specific lot is affected.
Look for the lot number 07MA2232 on the packaging to confirm if it's affected.
The recall is due to stability concerns, not immediate safety risks. The product may not work correctly over time.
Check for the lot number 07MA2232 on the packaging. The product expires April 30, 2023.
The recall doesn't specify a return process. Contact Direct Rx for guidance.
We’ve drafted a message you can send Direct Rx to request your refund or repair — edit it as you like.
Subject: Recall D-0101-2023 — Direct Rx Direct Rx Hello, I own a Direct Rx that is covered by recall D-0101-2023 from Direct Rx. I’m writing to arrange the remedy described in the recall (a refund, repair, or replacement as applicable). Could you please tell me the next steps to resolve this? Thank you.
Experiences, tips, and questions from readers. Every comment is reviewed before it appears.
No comments yet — be the first to share your experience.
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
